1,657 results on '"Hydroxychloroquine adverse effects"'
Search Results
2. Hydroxychloroquine-Induced Hypoglycemia in a Patient Without Diabetes.
- Author
-
Mcknight M, Cutshall BT, Sakaan S, Al Hommos NA, and Wells DA
- Subjects
- Humans, Middle Aged, Female, Blood Glucose drug effects, Blood Glucose metabolism, Hydroxychloroquine adverse effects, Hypoglycemia chemically induced, Antirheumatic Agents adverse effects, Antirheumatic Agents administration & dosage
- Abstract
Hydroxychloroquine is a disease-modifying antirheumatic drug commonly used in the treatment of autoimmune diseases. Although rare, hydroxychloroquine is associated with hypoglycemia in patients with or without diabetes due to its ability to alter insulin metabolism. There have been several cases described in the literature, but none of which, to our knowledge, detail follow-up and time to resolution of hypoglycemia. We describe a 55-year-old female who presents for episodes of hypoglycemia. She reported hypoglycemic symptoms and fasting blood glucoses in the 60-70s mg/dL regularly. Based on the Naranjo adverse drug reaction probability scale, hydroxychloroquine was the probable etiology of her hypoglycemic episodes due to the improvement at her 3-month follow up appointment after discontinuing the drug. Providers should be mindful of the hypoglycemia risk when using hydroxychloroquine and be aware that the effects may take an extended amount of time to resolve given the drug's long half-life., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
3. Prevalence, Outcomes, and Predictors of Prolonged Corrected QT Interval in Hydroxychloroquine-Naïve Hospitalized COVID-19 Patients.
- Author
-
Gupta P, Gupta A, Gupta K, Bansal S, Sharma M, and Balakrishnan I
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Prevalence, Risk Factors, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, SARS-CoV-2, COVID-19 Drug Treatment, Electrocardiography, Hospitalization, Risk Assessment, Aged, 80 and over, Heart Rate, COVID-19 mortality, COVID-19 diagnosis, COVID-19 epidemiology, COVID-19 complications, Long QT Syndrome diagnosis, Long QT Syndrome epidemiology, Long QT Syndrome mortality, Long QT Syndrome physiopathology, Hospital Mortality
- Abstract
The studies regarding prevalence, outcomes, and predictors of prolonged corrected QT (QTc) among COVID-19 patients not on QTc-prolonging medication are not available in the literature. In this retrospective cohort study, the QTc of 295 hospital-admitted COVID-19 patients was analyzed and its association with in-hospital mortality was determined. The QTc was prolonged in 14.6% (43/295) of the study population. Prolonged QTc was seen in patients with older age (P = 0.018), coronary artery disease (P = 0.001), congestive heart failure (P = 0.042), elevated N-terminal-pro-B-type natriuretic peptide (NT-ProBNP) (P < 0.0001), and on remdesivir (P = 0.046). No episode of torsades de pointes arrhythmia or any arrhythmic death was observed among patients with prolonged QTc. The mortality was significantly high in patients with prolonged QTc (P = 0.003). The multivariate logistic regression analysis showed coronary artery disease (odds ratio (OR): 4.153, 95% CI 1.37-14.86; P = 0.013), and NT-ProBNP (ng/L) (OR: 1.000, 95% CI 1.000-1.000; P = 0.007) as predictors of prolonged QTc. The prolonged QTc was associated with the worst in-hospital survival (p by log-rank 0.001). A significant independent association was observed between prolonged QTc and in-hospital mortality in multivariate cox-regression analysis (adjusted hazard ratio: 3.861; (95% CI 1.719-6.523), P < 0.0001). QTc was found to be a marker of underlying comorbidities among COVID-19 patients. Prolonged QTc in hospitalized COVID-19 patients was independently associated with in-hospital mortality., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: A multicenter retrospective study.
- Author
-
Obijiofor CE, Sikora M, Liu L, Stern MJ, Hena KM, Mazori DR, Friedman S, Mandal S, and Caplan AS
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Adult, Aged, Electrocardiography, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Sarcoidosis drug therapy, Skin Diseases drug therapy, Skin Diseases chemically induced, Long QT Syndrome chemically induced
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
5. Taking hydroxychloroquine to heart.
- Author
-
Heymann WR
- Subjects
- Humans, Cardiotoxicity etiology, Cardiotoxicity prevention & control, Antirheumatic Agents adverse effects, Antirheumatic Agents therapeutic use, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
6. The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom.
- Author
-
Yusuf IH, Han RC, Downes SM, and Sharma SM
- Subjects
- Humans, Incidence, Prospective Studies, United Kingdom epidemiology, Male, Female, Middle Aged, Adult, Aged, Hydroxychloroquine adverse effects, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Retinal Diseases epidemiology, Antirheumatic Agents adverse effects, Visual Acuity
- Abstract
Background: Retinal monitoring is recommended for hydroxychloroquine users to detect pre-symptomatic retinopathy and preserve visual function. However, the incidence of hydroxychloroquine retinopathy and monitoring coverage in the U.K. are incompletely characterised. Moreover, the visual benefits of monitoring for retinopathy - recommended for over 70,000 long-term hydroxychloroquine users in the U.K. - remain unproven., Methods: A national, prospective observational study was undertaken with the British Ophthalmological Surveillance Unit (BOSU). Newly diagnosed cases of hydroxychloroquine retinopathy in the U.K. were reported and data captured using a standardised questionnaire over 3.5 years (July 2018-Dec 2021). The frequency of retinopathy and coverage of monitoring amongst long-term users was estimated. Visual function was compared between asymptomatic individuals detected on monitoring and those presenting with visual symptoms. The clinical characteristics, dosing and management of reported cases were captured., Results: The annualised number of incident cases of hydroxychloroquine retinopathy was 29-57, with an annualised frequency of 0.04-0.08% amongst long-term users (~1 in 1247-2625). The coverage of monitoring was approximately 2.6-5.5%. Visual acuity (0.1 vs. 0.22 logMAR; p = 0.007) and visual field mean deviation (-3.73 dB vs. -8.69 dB; p = 0.017) were better preserved in asymptomatic individuals compared to those presenting with visual symptoms., Conclusion: These data support the efficacy of monitoring in the preservation of visual function in patients with hydroxychloroquine retinopathy at diagnosis. The overall population coverage of monitoring was low, consistent with the high proportion of symptomatic patients at diagnosis. This study presents a method for evaluating the yield of monitoring for hydroxychloroquine retinopathy in the U.K., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. Association between hydroxychloroquine intake and damage to the outer nuclear layer in eyes without manifest retinal toxicity.
- Author
-
Salameh N, Doumit CA, Jalkh E, and Nehme J
- Subjects
- Humans, Female, Male, Middle Aged, Case-Control Studies, Adult, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Aged, Retrospective Studies, Visual Acuity, Hydroxychloroquine adverse effects, Hydroxychloroquine toxicity, Tomography, Optical Coherence methods, Antirheumatic Agents adverse effects, Antirheumatic Agents toxicity, Retina drug effects, Retina pathology, Retina diagnostic imaging
- Abstract
Background: Hydroxychloroquine (HCQ) is widely used to treat various autoimmune diseases but carries a risk of retinal toxicity, particularly with prolonged use. Despite advancements, uncertainty persists regarding optimal screening methods. Recent advances in OCT have enabled early detection of retinal damage, with studies suggesting that thinning of specific retinal layers may be an early indicator of toxicity. However, there is a gap in research on outer nuclear layer (ONL) thinning in HCQ users without apparent retinal toxicity. This information is crucial for improving screening and identifying the ONL as a reliable biomarker for screening. Therefore, this study aimed to investigate the association between HCQ intake and ONL damage in eyes without manifest retinal toxicity., Methods: A case‒control study was conducted at the ophthalmology department of Eye and Ear Hospital International from July 2022 to June 2023. The study included 20 individuals on HCQ and 20 age-matched controls. The data were obtained through chart reviews, and participants underwent comprehensive ophthalmic assessments., Results: A total of 80 eyes were analyzed. Patients on HCQ exhibited significantly thinner perifoveal, parafoveal, and overall ONL compared to controls (P < .001, P < .012, and P < .004, respectively). Similarly, this association was found in the nasal, inferior, and temporal quadrants of both the inner (region 3: P < .01, region 4: P < .001, and region 5: P < .03) and outer zones (region 7: P < .04, region 8: P < .001, region 9: P < .02), most pronounced in the inferior regions. The cumulative dose was weakly associated with decreased ONL thickness only in the nasal quadrant of the inner zone (region 3: P < .047). Correlation analysis of the initial and most recent OCT scans in the same individuals revealed a weak association with ONL thinning in the central zone (region 1: P < .0048)., Conclusion: The thickness of the ONL can significantly decrease in patients taking HCQ, even in the absence of of manifest retinal toxicity. This study is the first to evaluate this association in eyes with negative screening and diagnostic tests for HCQ retinopathy. The findings suggest that ONL thickness could serve as an early diagnostic indicator for HCQ retinal toxicity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage.
- Author
-
Eviatar T, Yahalom R, Livnat I, Elboim M, Elkayam O, Chodick G, Rosenberg V, and Paran D
- Subjects
- Humans, Female, Male, Retrospective Studies, Middle Aged, Adult, Cardiovascular Diseases epidemiology, Logistic Models, Antirheumatic Agents therapeutic use, Antirheumatic Agents adverse effects, Diabetes Mellitus epidemiology, Diabetes Mellitus drug therapy, Hypertension epidemiology, Hypertension drug therapy, Hypertension complications, Young Adult, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic epidemiology, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Glucocorticoids therapeutic use, Glucocorticoids adverse effects, Comorbidity, Osteoporosis epidemiology
- Abstract
Objective: To assess treatment patterns and the association between long-term glucocorticoid (GC) and hydroxychloroquine (HCQ) use and damage accrual in patients with systemic lupus erythematosus (SLE)., Methods: A retrospective study including patients with SLE using the computerised database of a large health maintenance organisation. Patients were matched with subjects from the general population. Multivariable logistic regression models were used to assess the association between GC cumulative daily doses, HCQ and comorbidities: Osteoporosis, cardiovascular disease (CVD), hypertension and diabetes mellitus. Models were adjusted for age, sex, socioeconomic status, smoking, disease duration and HCQ use., Results: A total of 1073 patients with SLE were included, 87.79% were women. The age at first diagnosis was 37.23±14.36 and the SLE disease duration was 12.89±6.23 years. Initiation of HCQ within 12 months of SLE diagnosis increased from 51.02% in 2000 to 83.67% in 2010 and 93.02% in 2018. The annual usage of GC gradually decreased from 45.34% in 2000 to 30.76% in 2020. CVD and osteoporosis were more prevalent in SLE than in the general population. Multivariable logistic regression models revealed increased odds for comorbidities in patients receiving a mean daily dose of prednisone of more than 5 mg/day compared with those receiving 5 mg/day or less., Conclusions: CVD and osteoporosis were more prevalent in SLE than in the general population. The dose and frequency of GC treatment in patients with SLE have decreased over the years. Prednisone usage in doses exceeding 5 mg/day is associated with significantly increased odds of osteoporosis and CVD., Competing Interests: Competing interests: RY, IL and ME are employees of AstraZeneca. TE and DP received consultant fees from AstraZeneca., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
9. Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
- Author
-
Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV, Dhorda M, Ngernseng T, Waithira N, Ekkapongpisit M, Watson JA, Chandna A, Nelwan EJ, Hamers RL, Etyang A, Beg MA, Sow S, Yavo W, Allabi AC, Basnyat B, Sharma SK, Amofa-Sekyi M, Yonga P, Adler A, Yuentrakul P, Cope T, Thaipadungpanit J, Rienpradub P, Imwong M, Abdad MY, Blacksell SD, Tarning J, Goudjo FF, Dossou AD, Konaté-Touré A, Assi SB, Ouffoué K, Nasronudin N, Rachman BE, Romadhon PZ, Dewanto DD, Heryana MO, Novi T, Pasaribu AP, Mutiara M, Nasution MPR, Khairunnisa K, Dalimunthe FA, Airlangga E, Fahrezzy A, Subronto Y, Ananda NR, Rahardjani M, Rimainar A, Lucinde RK, Timbwa M, Onyango OE, Agutu C, Akech S, Hamaluba M, Kipyego J, Ngachi O, Haidara FC, Traoré OY, Diarra F, Khanal B, Dahal P, Shrestha S, Rijal S, Kabore Y, Adehossi E, Guindo O, Qamar FN, Kazi AM, Woodrow CJ, Laird S, Cheeba M, Ayles H, Cheah PY, Taylor WRJ, Batty EM, Chotivanich K, Pukrittayakamee S, Phumratanaprapin W, von Seidlein L, Dondorp A, Day NPJ, and White NJ
- Subjects
- Humans, Double-Blind Method, Female, Adult, Male, Middle Aged, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Treatment Outcome, Young Adult, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Chloroquine therapeutic use, Chloroquine adverse effects, COVID-19 Drug Treatment, COVID-19 prevention & control, COVID-19 epidemiology, SARS-CoV-2
- Abstract
Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use., Methods and Findings: Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507., Interpretation: In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs., Trial Registration: ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947., Competing Interests: NJW and LvS are members of the PLOS Medicine Editorial Board. The rest of the authors have declared that no competing interests exist., (Copyright: © 2024 Schilling et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
10. The assessment of structural and functional test results for early detection of hydroxychloroquine macular toxicity.
- Author
-
Sonalcan V, Çakir B, Özkan Aksoy N, Özata Gündoğdu K, Türkoğlu Şen EB, and Alagöz G
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Nerve Fibers pathology, Nerve Fibers drug effects, Visual Acuity, Visual Field Tests methods, Aged, Hydroxychloroquine adverse effects, Tomography, Optical Coherence methods, Visual Fields physiology, Visual Fields drug effects, Antirheumatic Agents adverse effects, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Macula Lutea drug effects, Macula Lutea pathology, Macula Lutea diagnostic imaging, Retinal Ganglion Cells pathology, Retinal Ganglion Cells drug effects, Contrast Sensitivity physiology, Contrast Sensitivity drug effects, Early Diagnosis, Fluorescein Angiography methods
- Abstract
Purpose: To assess structural (optical coherence tomography, fundus autofluorescence) and functional (contrast sensitivity and visual field) test results which were used for detecting early retinal changes in patients using oral hydroxychloroquine., Methods: Patients using oral hydroxychloroquine for at least one year were divided into two groups according to the duration of drug use. Groups 1 and 2 consisted of patients with drug use for more than 5 years and 1-5 years, respectively. The drug-using groups were compared with the control group. The mean retinal nerve fiber layer (RNFL), central macular thickness (CMT), ganglion cell-inner plexiform layer (GC-IPL), static 10-2 visual field, fundus autofluorescence (FAF) imaging, and contrast sensitivity tests were performed and statistically compared between groups., Results: Median and temporal quadrant RNFL thicknesses were found to be statistically significantly lower in the drug groups. In the drug groups, the GC-IPL sectoral and mean thicknesses were found to be statistically lower in all quadrants. Central macular thickness was also found to be similar in all three groups. There was no significant difference between the groups in visual field parameters. Macular FAF images were significantly higher in the drug users, but there was no significant difference between the three groups in foveal FAF images. Contrast sensitivity measurements were significantly lower in the drug groups than in the control group at all spatial frequencies except 6 and 18 cycles/degree., Conclusions: The combined use of structural and functional tests in patients using hydroxychloroquine provides useful information in detecting early retinal changes., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
11. Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial.
- Author
-
You Y, Zhou Z, Wang F, Li J, Liu H, Cheng X, Su Y, Chen X, Zheng H, Sun Y, Shi H, Hu Q, Xu J, Teng J, Yang C, and Ye J
- Subjects
- Humans, Female, Adult, Male, Middle Aged, Drug Therapy, Combination, Adolescent, Immunosuppressive Agents therapeutic use, Young Adult, China, Treatment Outcome, Mycophenolic Acid therapeutic use, Lupus Erythematosus, Systemic drug therapy, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Prednisone therapeutic use, Prednisone adverse effects
- Abstract
Importance: Anti-double-stranded DNA (dsDNA) antibody has been reported to have a close relationship with systemic lupus erythematosus (SLE) flares and participates in the pathogenesis of lupus nephritis (LN) as well as causing damage to other organs. However, whether early use of mycophenolate mofetil (MMF) could prevent SLE flares is not clear., Objective: To assess the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate compared with prednisone and hydroxychloroquine sulfate alone in patients with SLE., Design, Setting, and Participants: This investigator-initiated, multicenter, observer-blinded randomized clinical trial enrolled 130 participants aged 18 to 65 years and was conducted in 3 hospitals across China. Treatment-naive patients with newly diagnosed SLE, a high titer of anti-dsDNA antibody, and no major organ involvement were included. The study was started September 1, 2018, and the follow-up was completed September 30, 2021. Data were analyzed from December 1, 2021, to March 31, 2022., Interventions: Patients were randomized 1:1 to receive oral prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) (control group) or prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) plus MMF (500 mg twice daily) (MMF group) for 96 weeks., Main Outcomes and Measures: The primary outcome was the proportion of patients presenting with flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare Index. The secondary outcomes included the proportion with lupus low disease activity state at week 96, 36-Item Short Form Health Survey scores before and after treatment, proportion of adverse events (AEs), and changes in SLEDAI-2000 scores and prednisone doses., Results: Among 130 randomized patients (mean [SD] age, 34.5 [12.5] years; 112 [86.2%] women), 119 (91.5%) completed the follow-up. The risk of severe flare was significantly lower in the MMF group (7 of 65 [10.8%]) vs the control group (18 of 65 [27.7%]) (relative risk [RR], 0.39 [95% CI, 0.17-0.87]; P = .01). Additionally, 1 of 65 patients in the MMF group (1.5%) and 9 of 65 in the control group (13.8%) manifested LN (RR, 0.11 [95% CI, 0.01-0.85]; P = .008). Most common serious study drug-related AEs were infections (20 of 65 [30.8%] in the control group and 22 of 65 [33.8%] in the MMF group)., Conclusions and Relevance: The findings of this randomized clinical trial suggest that MMF may reduce the rate of severe flare and lower the incidence of LN in patients with new-onset SLE and a high titer of anti-dsDNA antibody without major organ involvement., Trial Registration: Chinese Clinical Trial Registry: ChiCTR1800017540.
- Published
- 2024
- Full Text
- View/download PDF
12. Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial.
- Author
-
Ma J, Zeng M, Hsu CJ, Li D, Fok MN, Jiang Y, Li Q, Ma J, Zhou J, Chen BS, and Li F
- Subjects
- Humans, Female, Male, Treatment Outcome, Middle Aged, Adult, Time Factors, Pain Measurement, Biomarkers blood, Aged, Inflammation Mediators blood, Methotrexate adverse effects, Methotrexate administration & dosage, Methotrexate therapeutic use, Hydroxychloroquine adverse effects, Hydroxychloroquine administration & dosage, Hydroxychloroquine therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid blood, Drug Therapy, Combination, Antirheumatic Agents adverse effects, Antirheumatic Agents administration & dosage, Antirheumatic Agents therapeutic use, Quality of Life
- Abstract
Objective: To explore the efficacy and safety of combination therapy with methotrexate (MTX) plus hydroxychloroquine (HCQ) vs. MTX monotherapy in patients with rheumatoid arthritis (RA)., Methods: Sixty patients without prior RA treatments were randomly allocated in a 1:1 ratio to two groups: one receiving MTX plus HCQ, and the other receiving MTX monotherapy. We conducted a comparative analysis before and after the 12-week trial, evaluating the visual analogue scale (VAS), the disease activity score in 28 joints (DAS), serum inflammatory factor (including serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), as well as the outcome of the World Health Organization Quality of Life Brief Version questionnaire (WHOQOL-BREF) and the treatment-emergent adverse events (TEAEs) for all the participants in the study., Results: At the 12th week of the trial, a more remarkable decrease in pain score (VAS), disease activity score (DAS), and serum inflammatory factor levels could be noticed in individuals on the combination therapy. The quality of life score was as well found to be higher in the MTX + HCQ group than the MTX monotherapy group. The incidence of adverse reactions in the MTX + HCQ and the MTX monotherapy groups were 10.00% and 6.67%, respectively. However, no statistical significance could be observed (p > .05)., Conclusion: In our study, both the MTX + HCQ combination therapy and MTX monotherapy demonstrated improvements in symptoms, conditions and quality of life for patients with RA. Notably, the combination therapy could achieve better outcomes across all indices compared to MTX monotherapy, highlighting its potential as the optimal first-line treatment for RA. © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd., (© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
13. Slate Grey Eyelid Pigmentation in a Patient With Hemochromatosis and Prior Hydroxychloroquine Use.
- Author
-
Azad AD, Chiou CA, Stagner AM, and Freitag SK
- Subjects
- Humans, Eyelid Diseases diagnosis, Eyelid Diseases chemically induced, Male, Female, Antirheumatic Agents adverse effects, Eyelids, Pigmentation Disorders chemically induced, Pigmentation Disorders diagnosis, Middle Aged, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Hemochromatosis diagnosis, Hemochromatosis complications
- Abstract
Competing Interests: S.K.F.: Sling (Consultant), Viridian (Consultant), WL Gore (Consultant), Poriferous (Consultant), Medtronic (Consultant), ASPEN/Third Rock (consultant), Lassen (consultant), Immunovant (consultant), and Thieme and Springer (textbook royalties). The other authors have no financial or conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
14. Factors associated with early hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus.
- Author
-
Araújo O, Hernández-Negrín H, Casaroli-Marano RP, Hernández-Rodríguez J, Adán A, Espinosa G, Pelegrín L, and Cervera R
- Subjects
- Humans, Female, Male, Retrospective Studies, Adult, Follow-Up Studies, Middle Aged, Visual Acuity, Visual Fields physiology, Fluorescein Angiography methods, Risk Factors, Time Factors, Hydroxychloroquine adverse effects, Lupus Erythematosus, Systemic drug therapy, Tomography, Optical Coherence methods, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Antirheumatic Agents adverse effects, Retina drug effects, Retina pathology
- Abstract
Purpose: Hydroxychloroquine is currently recommended for the treatment of systemic lupus erythematosus (SLE), but it can cause irreversible retinal toxicity. This study aimed to identify factors associated with early hydroxychloroquine-induced retinal toxicity in patients with SLE from a single centre for 20 years., Methods: SLE patients diagnosed between 1998 and 2017 and followed up for at least 1 year were included. Demographic, clinical, laboratory and therapeutic data were collected from the electronic medical records and retrospectively analysed. Early hydroxychloroquine-induced retinal toxicity was defined as the development of macular toxicity within the first 5 years of hydroxychloroquine treatment., Results: A total of 345 patients followed for a median of 15 years were analysed; 337 (97.7%) patients received hydroxychloroquine, 38 (11.3%) of them presented with retinal toxicity, and 10 (3%) developed early retinal toxicity. These patients had a mean treatment duration of 3.3 years with a mean cumulative dose of 241 g. Patients were diagnosed by visual field (VF) and fundoscopy, and two were also assessed using spectral domain optical coherence tomography (SD-OCT). The median (IQR) age of patients with early toxicity was 56 (51-66) years, and 80% were female. Factors independently associated with early hydroxychloroquine-induced retinal toxicity were lupus anticoagulant positivity (OR 4.2; 95% CI 1.2-15.5) and hypercholesterolaemia (OR 5.6; 95% CI 1.5-21.5)., Conclusion: Our results suggest that lupus anticoagulant positivity and hypercholesterolaemia among SLE patients may be risk factors for early hydroxychloroquine-induced retinal toxicity, regardless of the dose or duration of treatment., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
15. Clinical features of ocular damage in systemic lupus erythematosus and risk factors for hydroxychloroquine-related complications.
- Author
-
Cheng T, Gu X, Yang Z, Wang C, Chen Y, and Zhao X
- Subjects
- Humans, Eye Diseases chemically induced, Eye Diseases epidemiology, Eye Diseases immunology, Retinal Diseases chemically induced, Retinal Diseases epidemiology, Retinal Diseases immunology, Risk Factors, Antirheumatic Agents adverse effects, Antirheumatic Agents therapeutic use, Hydroxychloroquine administration & dosage, Hydroxychloroquine adverse effects, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic immunology
- Abstract
Ocular damage in systemic lupus erythematosus (SLE) may cause insidious visual impairment, but its clinical features and the risk of hydroxychloroquine (HCQ)-related complications are still controversial. We performed a meta-analysis to evaluate ocular damage in SLE, the correlation between eye and systemic involvement, and the ocular side effects of treatment. The database PubMed, Embase, and Ovid were used for literature from reception to July, 2023, and the calculation was carried out with R. About 48,693 patients from 66 studies were included. The results indicated that ocular damage in SLE was insidious, appearing in 28 % of patients with no complaints. The most common symptoms and manifestations were dry eye (30 %) and keratoconjunctivitis sicca (26 %). Retinopathy was detected in 10 % of patients and was related to antiphospholipid antibodies (25 % versus 8 %). The proportion of retinopathy also significantly increased in patients with lupus nephropathy or neuropsychiatric systemic lupus erythematosus (risk ratio of 2.29 and 1.95, respectively). HCQ was used in 82 % of patients, of which 4 % suffered from ocular toxicity. HCQ-related retinopathy was dose-dependent. Dosage below 5 mg/kg/d was relatively effective and safe for long-term use, while routine examination was recommended., Competing Interests: Declaration of Competing Interest There are no financial/conflicting interests to disclose for authors., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Challenges and Reflections on Pandemic Disinformation: The Case of Hydroxychloroquine and the Implications for Global Public Health.
- Author
-
Silva HM
- Subjects
- Humans, Pandemics, Global Health, Communication, Social Media, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Public Health, COVID-19 Drug Treatment, COVID-19 epidemiology, SARS-CoV-2
- Abstract
This text addresses the implications of misinformation during the COVID-19 pandemic, focusing on the use of hydroxychloroquine (HCQ) and other drugs based on a specific publication. The article titled "Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate," published in 2024 in the journal Biomedicine and Pharmacotherapy, reveals 17 000 deaths associated with the inappropriate use of HCQ in 6 countries, excluding Brazil and India. The dissemination of ineffective drugs, the persistence in recommending HCQ in Brazil, and the lack of an effective response from academia underscore the fragility of public health systems under pressure. Transparent communication between the scientific community and the public is vital, particularly considering studies, such as the one published in Nature Communications in 2021, which warns of the risks of chloroquine. The text highlights the influence of social media in spreading unverified information and emphasizes the need for criminal liability for those contributing to the spread of misinformation. It concludes by underlining the importance of learning from past mistakes to build a more resilient and informed future in the field of public health., Competing Interests: Author Disclosures Author disclosure forms can be accessed below in the Supplemental Material section., (Copyright © 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Hydroxychloroquine-induced acute generalized exanthematous pustulosis (AGEP) treated with secukinumab.
- Author
-
Wang Y, Liu Y, Feng C, Wang M, Wang Q, and Geng S
- Subjects
- Humans, Female, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Middle Aged, Male, Antirheumatic Agents adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Acute Generalized Exanthematous Pustulosis etiology, Acute Generalized Exanthematous Pustulosis pathology, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
18. Lipodystrophia centrifugalis abdominals infantilis presenting as a giant ulceration and treatment with hydroxychloroquine and baricitinib.
- Author
-
Zhao X, Miao C, Chen Y, Xiang X, Liu Y, Zhaoyang W, and Xu Z
- Subjects
- Humans, Male, Lipodystrophy drug therapy, Lipodystrophy diagnosis, Skin Ulcer drug therapy, Skin Ulcer diagnosis, Drug Therapy, Combination, Pyrazoles adverse effects, Pyrazoles therapeutic use, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Sulfonamides therapeutic use, Sulfonamides adverse effects, Azetidines therapeutic use, Azetidines adverse effects, Purines adverse effects, Purines therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
19. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry.
- Author
-
Dernoncourt A, Hedhli K, Abisror N, Cheloufi M, Cohen J, Kolanska K, McAvoy C, Selleret L, Ballot E, Mathieu d'Argent E, Chabbert Buffet N, Fain O, Kayem G, and Mekinian A
- Subjects
- Humans, Female, Pregnancy, Adult, France epidemiology, Prospective Studies, Pregnancy Outcome, Young Adult, Middle Aged, Adolescent, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Registries, Abortion, Habitual epidemiology
- Abstract
Study Question: What are the outcomes of pregnancies exposed to hydroxychloroquine (HCQ) in women with a history of recurrent pregnancy loss (RPL), and what factors predict the course of these pregnancies beyond the first trimester?, Summary Answer: In our cohort of pregnancies in women with a history of RPL exposed to HCQ early in pregnancy, we found that the only factor determining the success of these pregnancies was the number of previous miscarriages., What Is Known Already: Dysregulation of the maternal immune system plays a role in RPL. HCQ, with its dual immunomodulating and vascular protective effects, is a potential treatment for unexplained RPL., Study Design, Size, Duration: The FALCO (Facteurs de récidive précoce des fausses couches) registry is an ongoing French multicenter infertility registry established in 2017 that includes women (aged from 18 to 49 years) with a history of spontaneous RPL (at least three early miscarriages (≤12 weeks of gestation (WG)) recruited from several university hospitals., Participants/materials, Setting, Methods: Spontaneous pregnancies enrolled in the FALCO registry with an exposure to HCQ (before conception or at the start of pregnancy) were included. Pregnancies concomitantly exposed to tumor necrosis factor inhibitors, interleukin-1 and -2 inhibitors, intravenous immunoglobulin, and/or intravenous intralipid infusion, were excluded. Concomitant treatment with low-dose aspirin (LDA), low-molecular weight heparin (LMWH), progesterone, and/or prednisone was allowed. All patients underwent the recommended evaluations for investigating RPL. Those who became pregnant received obstetric care in accordance with French recommendations and were followed prospectively. The main endpoint was the occurrence of a pregnancy continuing beyond 12 WG, and the secondary endpoint was the occurrence of a live birth., Main Results and the Role of Chance: One hundred pregnancies with HCQ exposure in 74 women were assessed. The mean age of the women was 34.2 years, and the median number of previous miscarriages was 5. Concomitant exposure was reported in 78 (78%) pregnancies for prednisone, 56 (56%) pregnancies for LDA, and 41 (41%) pregnancies for LMWH. Sixty-two (62%) pregnancies ended within 12 WG, the other 38 (38%) continuing beyond 12 WG. The risk of experiencing an additional early spontaneous miscarriage increased with the number of previous miscarriages, but not with age. The distributions of anomalies identified in RPL investigations and of exposure to other drugs were similar between pregnancies lasting ≤12 WG and those continuing beyond 12WG. The incidence of pregnancies progressing beyond 12 WG was not higher among pregnancies with at least one positive autoantibody (Ab) (i.e. antinuclear Ab titer ≥1:160, ≥1 positive conventional and/or non-conventional antiphospholipid Ab, and/or positive results for ≥1 antithyroid Ab) without diminished ovarian reserve (18/51, 35.3%) than among those without such autoantibody (18/45, 40.0%) (P = 0.63). Multivariate analysis showed that having ≤4 prior miscarriages was the only factor significantly predictive for achieving a pregnancy > 12 WG, after adjustment for age and duration of HCQ use prior to conception (adjusted odds ratio (OR) = 3.13 [1.31-7.83], P = 0.01)., Limitations, Reasons for Caution: Our study has limitations, including the absence of a control group, incomplete data for the diagnostic procedure for RPL in some patients, and the unavailability of results from endometrial biopsies, as well as information about paternal age and behavioral factors. Consequently, not all potential confounding factors could be considered., Wider Implications of the Findings: Exposure to HCQ in early pregnancy for women with a history of RPL does not seem to prevent further miscarriages, suggesting limited impact on mechanisms related to the maternal immune system., Study Funding/competing Interest(s): The research received no specific funding, and the authors declare no competing interests., Trial Registration Number: clinicaltrial.gov NCT05557201., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
- Published
- 2024
- Full Text
- View/download PDF
20. Lupus review is misleading about risk of hydroxychloroquine retinal toxicity.
- Author
-
Marmor MF
- Subjects
- Humans, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Retinal Diseases chemically induced, Lupus Erythematosus, Systemic drug therapy, Antirheumatic Agents adverse effects
- Abstract
Competing Interests: Declaration of Competing Interest None.
- Published
- 2024
- Full Text
- View/download PDF
21. Bilateral outer foveal microdefect in a patient with systemic lupus erythematosus using hydroxychloroquine - A case report.
- Author
-
Alves EM, Fonseca V, Moura CA, Oliveira IS, and Santiago MB
- Subjects
- Humans, Female, Antirheumatic Agents adverse effects, Antirheumatic Agents therapeutic use, Tomography, Optical Coherence, Adult, Visual Acuity, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic complications, Fovea Centralis pathology
- Abstract
Introduction: The association of outer foveal microdefect and LES or hydroxychloroquine use has not been established in current literature., Case Report: We present the first reported case of bilateral outer foveal microdefect ina a patient with systemic lúpus erythematosus using hydroxycloroquine., Discussion/conclusion: While it is not possible to definitively attribute the described findings in our patient to HCQ use, it is important to be aware of the possibility that the outer foveal microdefect may be caused by this medication. Therefore, patients on chronic HCQ therapy should be informed about the risk of potential visual adverse effects, so that appropriate interventions can be implemented if necessary., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
22. The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters.
- Author
-
Uyar S, Kök M, Ayan A, Coşkuner MA, Köker G, and Koca N
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Sjogren's Syndrome drug therapy, Drug Therapy, Combination, Levofloxacin therapeutic use, Levofloxacin administration & dosage, Levofloxacin adverse effects, Adult, SARS-CoV-2, COVID-19, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine administration & dosage, Electrocardiography drug effects, COVID-19 Drug Treatment, Azithromycin therapeutic use, Azithromycin adverse effects, Azithromycin administration & dosage, Long QT Syndrome chemically induced
- Abstract
Amidst the COVID-19 pandemic, hydroxychloroquine (HCQ) was widely administered despite limited data on its safety and efficacy. This study assesses the acute and chronic impacts of HCQ on electrocardiography (ECG) parameters alongside the effects of azithromycin and levofloxacin coadministration in patients with COVID-19. A comprehensive analysis was conducted on 109 COVID-19 patients receiving HCQ, with or without Azithromycin and/or Levofloxacin, and 51 long-term HCQ-treated Sjogren's syndrome (SS) patients. ECG parameters, including QTc interval, were meticulously evaluated against a control group of 109 COVID-19 patients without HCQ treatment. HCQ monotherapy, in combination with Levofloxacin, significantly prolonged the QTc interval in COVID-19 patients compared to controls. Notably, the combination of HCQ and Azithromycin demonstrated a mitigated impact on QTc prolongation. Long-term HCQ use in SS patients did not significantly affect QTc intervals, illustrating a distinct safety profile from short-term use in COVID-19 treatment. HCQ's impact on QTc prolongation is influenced by therapeutic context, coadministered drugs, and patient demographics. The findings underscore the necessity of cautious HCQ use, particularly in acute settings like COVID-19, where monitoring and consideration of drug interactions and patient-specific factors are critical., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
23. Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus.
- Author
-
Grimaldi L, Duchemin T, Hamon Y, Buchard A, Benichou J, Abenhaim L, Costedoat-Chalumeau N, and Moride Y
- Subjects
- Humans, Female, Male, Middle Aged, Case-Control Studies, Adult, Myocardial Infarction epidemiology, Myocardial Infarction chemically induced, Stroke epidemiology, Stroke prevention & control, Cohort Studies, France epidemiology, Thromboembolism epidemiology, Thromboembolism prevention & control, Risk Factors, Aged, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic complications, Antirheumatic Agents therapeutic use, Antirheumatic Agents adverse effects, Cardiovascular Diseases epidemiology
- Abstract
Importance: Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events. While hydroxychloroquine is thought to mitigate CV risk factors, its protective role against CV events, particularly arterial ones, remains to be confirmed., Objective: To evaluate the association between hydroxychloroquine and the risk of myocardial infarction (MI), stroke, and other thromboembolic events (OTEs) in patients with SLE., Design, Setting, and Participants: This cohort study using a nested case-control design was conducted within the National French Healthcare Database (SNDS), which represents 99% of the French population, from 2010 to 2020. Participants were the cohort of all patients with SLE recorded in the SNDS. Patients with SLE experiencing CV events during the study period were the case group; those without CV events were controls. The analysis period was from February 2022 to September 2023., Exposures: Hydroxychloroquine use within 365 days prior to the index date, defined as current (within 90 days), remote (91-365 days), or no exposure within the previous 365 days., Main Outcomes and Measures: Outcomes of interest were MI, stroke, and OTE, analyzed individually and as a composite outcome (primary analysis). Controls were matched to patients with CV events by age, sex, time since SLE onset and entry into the SNDS database, index date, prior antithrombotic and CV medication, chronic kidney disease, and hospitalization. Multivariable conditional logistic regression was performed using hydroxychloroquine exposure as the main independent variable., Results: The SLE cohort included 52 883 patients (mean [SD] age, 44.23 [16.09] years; 45 255 [86.6%] female; mean [SD] follow-up, 9.01 [2.51] years), including 1981 patients with eligible CV events and 16 892 matched control patients. There were 669 MI events, 916 stroke events, and 696 OTEs in the individual outcome studies. For current exposure to hydroxychloroquine, the adjusted odds were lower for composite CV events (odds ratio [OR], 0.63; 95% CI, 0.57-0.69) as well as for MI (OR, 0.72; 95% CI, 0.60-0.85), stroke (OR, 0.69; 95% CI, 0.60-0.81), and OTEs (OR, 0.58; 95% CI, 0.49-0.69) individually compared with no hydroxychloroquine exposure within 365 days., Conclusions and Relevance: In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes, highlighting the value of continuous hydroxychloroquine treatment in patients with SLE.
- Published
- 2024
- Full Text
- View/download PDF
24. Hydroxychloroquine, Chloroquine, and Arrhythmic Risk in Systemic Autoimmune Diseases: Focus More on the Patient and You Will Keep the Rhythm!
- Author
-
Golino M and Lazzerini PE
- Subjects
- Humans, Risk Factors, Risk Assessment, Antirheumatic Agents adverse effects, Antirheumatic Agents therapeutic use, Heart Rate drug effects, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Chloroquine adverse effects, Chloroquine therapeutic use, Autoimmune Diseases drug therapy, Autoimmune Diseases epidemiology, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac physiopathology
- Abstract
Competing Interests: The authors report no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
25. Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
- Author
-
Nikolic RPA, Virk MK, Buhler KA, Costenbader KH, Choi MY, and Weber BN
- Subjects
- Humans, Risk Assessment, Male, Female, Middle Aged, Adult, Risk Factors, Cardiotoxicity, Aged, Heart Rate drug effects, Young Adult, Treatment Outcome, Action Potentials drug effects, Adolescent, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic mortality, Hydroxychloroquine adverse effects, Antirheumatic Agents adverse effects, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac mortality, Arrhythmias, Cardiac physiopathology, Chloroquine adverse effects, Rheumatic Diseases drug therapy, Rheumatic Diseases mortality, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac epidemiology, Autoimmune Diseases chemically induced, Autoimmune Diseases diagnosis, Autoimmune Diseases mortality, Autoimmune Diseases drug therapy
- Abstract
Abstract: Hydroxychloroquine (HCQ) and chloroquine (CQ) are foundational treatments for several systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Concerns regarding the risk of cardiac arrhythmia and death have been raised, yet the burden of HCQ and CQ-related cardiac toxicities remains unclear. A systematic literature search was conducted in the MEDLINE and Embase databases for articles published between the earliest date and April 2023 reporting cardiac conduction abnormalities in patients with systemic autoimmune rheumatic diseases taking HCQ or CQ. Meta-analysis was performed to calculate the difference in mean corrected QT (QTc) interval and odds ratio of prolonged QTc interval in those taking HCQ or CQ versus not. Of 2673 unique records, 34 met the inclusion criteria, including 70,609 subjects. Thirty-three studies reported outcomes in HCQ and 9 in CQ. Five studies reported outcomes in RA, 11 in SLE, and 18 in populations with mixed rheumatic diseases. Eleven studies reported mean QTc and OR for prolonged QTc for meta-analysis, all reporting outcomes in HCQ. There was a significant increase in mean QTc (10.29 ms, P = 0.458) among HCQ users compared to non-HCQ users in patients with RA. There was no difference in mean QTc between HCQ and non-HCQ users in other systemic autoimmune rheumatic diseases. When rheumatic diseases were pooled, HCQ users were more likely to have prolonged QTc compared to non-HCQ users (odds ratio 1.57, 95% CI, 1.19, 2.08). The results of this study suggest that clinicians should be aware of potential adverse cardiac events of HCQ and consider QTc monitoring for patients on HCQ for the treatment of systemic autoimmune rheumatic diseases., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population-based retrospective study of 6408 patients.
- Author
-
Dong C, Chen BS, Wu CH, Chiu YM, Liao PL, and Perng WT
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Taiwan epidemiology, Risk Factors, Adult, Aged, Risk Assessment, Bone Density drug effects, Treatment Outcome, Time Factors, Protective Factors, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Arthritis, Rheumatoid diagnosis, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Osteoporosis epidemiology, Osteoporosis chemically induced, Osteoporosis diagnosis, Antirheumatic Agents adverse effects, Databases, Factual
- Abstract
Aim: Patients with rheumatoid arthritis (RA) are at a higher risk of osteoporotic fractures. Studies have shown that patients with Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) experienced an increase in bone mineral density (BMD) after receiving hydroxychloroquine (HCQ) treatment, indicating a potential protective effect against osteoporosis. Therefore, this study is to examine the relationship between HCQ usage and the risk of osteoporosis in patients diagnosed with RA., Methods: The retrospective cohort study used data from Taiwan's National Health Insurance Research Database (NHIRD) covering the period from January 2010 to December 2018, which included 14 050 newly diagnosed RA patients, subsequently divided into two groups: HCQ users and non-users. Propensity score matching (PSM) based on sex, age, urbanization, insured unit type, insured area, and comorbidities was conducted to match the groups. The primary outcome assessed was the evaluation of the risk of osteoporosis by employing a multivariable Cox proportional hazard regression model to calculate the adjusted hazard ratio (aHR)., Results: After PSM, a total of 6408 RA patients were included in the analysis (3204 HCQ users and 3204 non-users). There was no significantly higher risk of osteoporosis in HCQ users compared with non-users, aHR = 0.99 (95% CI: 0.82-1.196). Additionally, different durations of HCQ usage demonstrated a neutral effect on the risk of osteoporosis [HCQ <90 days, aHR = 0.88 (95% CI: 0.585-1.324); HCQ 90-180 days, aHR = 0.941 (95% CI: 0.625-1.418); HCQ >180 days, aHR = 1.019 (95% CI: 0.832-1.249)]., Conclusions: The study indicates that there is no significant association between the use of HCQ and the risk of osteoporosis in patients with RA., (© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
27. Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study.
- Author
-
Hagen K
- Subjects
- Humans, Data Interpretation, Statistical, SARS-CoV-2, COVID-19, Hydroxychloroquine adverse effects, Bias, COVID-19 Drug Treatment
- Abstract
The term "statistical significance," ubiquitous in the medical literature, is often misinterpreted, as is the " p -value" from which it stems. This article explores the implications of results that are numerically positive (e.g., those in the treatment arm do better on average) but not statistically significant. This lack of statistical significance is sometimes interpreted as strong, even decisive, evidence against an effect without due consideration of other factors. Three influential articles on hydroxychloroquine (HCQ) as a treatment for COVID-19 are illustrative. They all involve numerically positive results that were not statistically significant that were misinterpreted as strong evidence against HCQ's efficacy. These and related considerations raise concerns regarding the reliability of academic/medical reasoning around COVID-19 treatments, as well as more generally, and regarding the potential for bias stemming from conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
28. [Chloroquine and hydroxychloroquine maculopathy: a review of diagnostic and therapeutic guidelines in Hungarian and international clinical practice].
- Author
-
Fodor M, Lukács MÁ, Szekanecz Z, and Nagy ZZ
- Subjects
- Humans, Hungary, Antirheumatic Agents adverse effects, Electroretinography, Macular Degeneration drug therapy, Macular Degeneration diagnosis, Macular Degeneration chemically induced, Practice Guidelines as Topic, Hydroxychloroquine adverse effects, Chloroquine adverse effects, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Tomography, Optical Coherence
- Published
- 2024
- Full Text
- View/download PDF
29. Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities?
- Author
-
Abisheva S, Rutskaya-Moroshan K, Nuranova G, Batyrkhan T, and Abisheva A
- Subjects
- Humans, COVID-19, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Antimalarials therapeutic use, Antimalarials adverse effects, COVID-19 Drug Treatment, SARS-CoV-2, Rheumatic Diseases drug therapy, Rheumatic Diseases complications
- Abstract
Background and Objectives : The coronavirus disease of 2019 (COVID-19) pandemic has posed a serious threat to humanity and is considered a global health emergency. Antimalarial drugs (ADs) have been used in the treatment of immuno-inflammatory arthritis (IIA) and coronavirus infection (COVID-19). The aim of this review is to analyze the current knowledge about the immunomodulatory and antiviral mechanisms of action, characteristics of use, and side effects of antimalarial drugs. Material and Methods : A literature search was carried out using PubMed, MEDLINE, SCOPUS, and Google Scholar databases. The inclusion criteria were the results of randomized and cohort studies, meta-analyses, systematic reviews, and original full-text manuscripts in the English language containing statistically confirmed conclusions. The exclusion criteria were summary reports, newspaper articles, and personal messages. Qualitative methods were used for theoretical knowledge on antimalarial drug usage in AIRDs and SARS-CoV-2 such as a summarization of the literature and a comparison of the treatment methods. Results : The ADs were considered a "candidate" for the therapy of a new coronavirus infection due to mechanisms of antiviral activity, such as interactions with endocytic pathways, the prevention of glycosylation of the ACE2 receptors, blocking sialic acid receptors, and reducing the manifestations of cytokine storms. The majority of clinical trials suggest no role of antimalarial drugs in COVID-19 treatment or prevention. These circumstances do not allow for their use in the treatment and prevention of COVID-19. Conclusions : The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for COVID-19. Furthermore, the need for high doses in the treatment of viral infections increases the likelihood of gastrointestinal side effects, the prolongation of QT, and retinopathy. Large randomized clinical trials (RCTs) have refuted the fact that there is a positive effect on the course and results of COVID-19.
- Published
- 2024
- Full Text
- View/download PDF
30. SCREENING PRACTICES AND LATE DIAGNOSIS OF HYDROXYCHLOROQUINE RETINOPATHY IN ASIAN PATIENTS.
- Author
-
Ahn SJ and Kim JH
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Aged, Republic of Korea, Asian People ethnology, Hydroxychloroquine adverse effects, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Retinal Diseases ethnology, Antirheumatic Agents adverse effects, Delayed Diagnosis
- Abstract
Purpose: To investigate the associations between screening practices and late diagnosis in Asian patients with hydroxychloroquine retinopathy., Methods: In total, 92 Korean patients with hydroxychloroquine retinopathy were included and separated into late diagnosis and earlier diagnosis groups according to the retinopathy stage at the time of diagnosis. Details of screening practices regarding timing and modalities for baseline and annual monitoring examinations were compared between the two groups. Adherence to the current American Academy of Ophthalmology guidelines was compared between the two groups., Results: Timing of baseline and initial monitoring examinations was appropriate as per the Academy of Ophthalmology guidelines in only 5.3% of patients with late diagnosis. There were significant differences in the proportions of patients receiving initial monitoring at 5 years of use and those receiving annual monitoring between the late and earlier diagnosis groups ( P = 0.003 and <0.001, respectively). The duration from the start date of hydroxychloroquine therapy to the first monitoring examination was significantly prolonged in the late diagnosis group ( P < 0.001). Multivariate logistic regression revealed significant association of the time duration with the first monitoring examination ( P = 0.042) and age ( P = 0.028) with late diagnosis., Conclusion: Results of this study suggest that poor adherence to the Academy of Ophthalmology guideline, particularly delayed initial monitoring, may be associated with late diagnosis of hydroxychloroquine retinopathy.
- Published
- 2024
- Full Text
- View/download PDF
31. Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.
- Author
-
Garcia MC, Tsang K, Lohit S, Deng J, Schneider T, Matos Silva J, Mbuagbaw L, and Holbrook A
- Subjects
- Humans, Arrhythmias, Cardiac chemically induced, Randomized Controlled Trials as Topic, Adult, Chloroquine adverse effects, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine administration & dosage, Long QT Syndrome chemically induced
- Abstract
Objectives: We aimed to evaluate the high-quality literature on the frequency and nature of major adverse cardiac events (MACE) associated with either hydroxychloroquine (HCQ) or chloroquine (CQ)., Data Sources: We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onward using search strategies created in collaboration with medical science librarians., Study Selection and Data Extraction: Randomized controlled trials (RCTs) published in English language from January 1996 to September 2022, involving adult patients at least 18 years of age, were selected. Outcomes of interest were death, arrhythmias, syncope, and seizures. Random-effects meta-analyses were performed with a Treatment Arm Continuity Correction for single and double zero event studies., Data Synthesis: By study drug, there were 31 HCQ RCTs (n = 6677), 9 CQ RCTs (n = 622), and 1 combined HCQ-CQ trial (n = 105). Mortality was the most commonly reported MACE at 220 of 255 events (86.3%), with no reports of torsades de pointes or sudden cardiac death. There was no increased risk of MACE with exposure to HCQ-CQ compared with control (risk ratio [RR] = 0.90, 95% CI = 0.69-1.17, I
2 = 0%)., Relevance to Patient Care and Clinical Practice: These findings have important implications with respect to patient reassurance and updated guidance for prescribing practices of these medications., Conclusions: Despite listing as QT-prolonging meds, HCQ-CQ did not increase the risk of MACE., Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2024
- Full Text
- View/download PDF
32. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
- Author
-
Teboul A, Arnaud L, and Chasset F
- Subjects
- Humans, Chloroquine adverse effects, Chloroquine administration & dosage, Chloroquine therapeutic use, Quinacrine administration & dosage, Quinacrine therapeutic use, Quinacrine adverse effects, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic blood, Antimalarials adverse effects, Antimalarials administration & dosage, Antimalarials therapeutic use, Lupus Erythematosus, Cutaneous chemically induced, Lupus Erythematosus, Cutaneous drug therapy, Lupus Erythematosus, Cutaneous diagnosis, Lupus Erythematosus, Cutaneous blood, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine administration & dosage
- Abstract
Antimalarials (AMs), particularly hydroxychloroquine (HCQ) and chloroquine (CQ), are the cornerstone of the treatment for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). HCQ and CQ are recommended as first-line oral agents in all CLE guidelines. Initially thought to have potential therapeutic effects against COVID-19, HCQ has drawn significant attention in recent years, highlighting concerns over its potential toxicity among patients and physicians. This review aims to consolidate current evidence on the efficacy of AMs in CLE. Our focus will be on optimizing therapeutic strategies, such as switching from HCQ to CQ, adding quinacrine to either HCQ or CQ, or adjusting HCQ dose based on blood concentration. Additionally, we will explore the potential for HCQ dose reduction or discontinuation in cases of CLE or SLE remission. Our review will focus on the existing evidence regarding adverse events linked to AM usage, with a specific emphasis on severe events and those of particular interest to dermatologists. Last, we will discuss the optimal HCQ dose and the balance between preventing CLE or SLE flares and minimizing toxicity., (© 2024 Japanese Dermatological Association.)
- Published
- 2024
- Full Text
- View/download PDF
33. Comprehensive analysis of gastrointestinal side effects in COVID-19 patients undergoing combined pharmacological treatment with azithromycin and hydroxychloroquine: a systematic review and network meta-analysis.
- Author
-
Pacheco G, Lopes ALF, Oliveira AP, Corrêa WRM, Lima LDB, Souza MHLP, Teles AS, Nicolau LAD, and Medeiros JVR
- Subjects
- Humans, COVID-19, Ivermectin therapeutic use, Ivermectin adverse effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Azithromycin therapeutic use, Azithromycin adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, COVID-19 Drug Treatment, Gastrointestinal Diseases chemically induced, Gastrointestinal Diseases epidemiology, Network Meta-Analysis, Drug Therapy, Combination, SARS-CoV-2
- Abstract
During the COVID-19 pandemic, several drugs were repositioned and combined to quickly find a way to mitigate the effects of the infection. However, the adverse effects of these combinations on the gastrointestinal tract are unknown. We aimed investigate whether Hydroxychloroquine (HD), Azithromycin (AZ), and Ivermectin (IV) used in combination for the treatment of COVID-19, can lead to the development of gastrointestinal disorders. This is a systematic review and network meta-analysis conducted using Stata and Revman software, respectively. The protocol was registered with PROSPERO (CRD42023372802). A search of clinical trials in Cochrane Library databases, Embase, Web of Science, Lilacs, PubMed, Scopus and Clinicaltrials.gov conducted on November 26, 2023. The eligibility of the studies was assessed based on PICO criteria, including trials that compared different treatments and control group. The analysis of the quality of the evidence was carried out according to the GRADE. Six trials involving 1,686 COVID-19 patients were included. No trials on the association of HD or AZ with IV met the inclusion criteria, only studies on the association between HD and AZ were included. Nausea, vomiting, diarrhea, abdominal pain and increased transaminases were related. The symptoms of vomiting and nausea were evaluated through a network meta-analysis, while the symptom of abdominal pain was evaluated through a meta-analysis. No significant associations with these symptoms were observed for HD, AZ, or their combination, compared to control. Low heterogeneity and absence of inconsistency in indirect and direct comparisons were noted. Limitations included small sample sizes, varied drug dosages, and potential publication bias during the pandemic peak. This review unveils that there are no associations between gastrointestinal adverse effects and the combined treatment of HD with AZ in the management of COVID-19, as compared to either the use of a control group or the administration of the drugs individually, on the other hand, highlighting the very low or low certainty of evidence for the evaluated outcomes. To accurately conclude the absence of side effects, further high-quality randomized studies are needed.
- Published
- 2024
- Full Text
- View/download PDF
34. Exome sequencing and genome-wide association analyses unveils the genetic predisposition in hydroxychloroquine retinopathy.
- Author
-
Chiu HI, Cheng HC, Wu CC, Chen SJ, Hwang DK, Huang YM, Chou YB, Lin PK, Lin TC, Chen KH, Lin PY, Chang YF, and Wang AG
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Visual Acuity, Polymorphism, Single Nucleotide, Hydroxychloroquine adverse effects, Genome-Wide Association Study, Retinal Diseases genetics, Retinal Diseases chemically induced, Genetic Predisposition to Disease, Exome Sequencing, Antirheumatic Agents adverse effects
- Abstract
Objectives: To unveil the candidate susceptibility genes in chloroquine/hydroxychloroquine (CQ/HCQ) retinopathy using whole exome sequencing (WES) and genome-wide association study (GWAS)., Methods: Patients with a diagnosis of CQ/HCQ retinopathy based on the comprehensive demographic and ocular examination were included. The peripheral blood was extracted for WES and GWAS analyses. The Chinese Han Southern database from 1000 genomes was used as control group to compare the affected percentage. Multivariate logistic regression analysis adjusted for age, HCQ dose, duration and renal disease were used to analyze the correlation between genetic variants and visual outcome. A poor vision outcome was defined as visual acuity <6/12. An abnormal anatomical outcome was defined as disruption of ellipsoid zone in the fovea., Results: Twenty-nine patients with an average age of 60.9 ± 13.4 years, treatment duration of 12.1 ± 6.2 years, daily dose of 8.5 ± 4.1 mg/kg, and the cumulative dose of 1637.5 ± 772.5 g, were genotyped. Several candidate genes associated with CQ/HCQ retinopathy were found, including RP1L1, RPGR and RPE65, with a difference of affected percentage over 50% in mutation between the case and control groups. New foci in CCDC66: rs56616026 (OR = 63.43, p = 1.63 × 10
-8 ) and rs56616023 (OR = 104.7, p = 5.02 × 10-10 ) were identified significantly associated with HCQ retinopathy. Multivariate analysis revealed increased genetic variants were significantly associated with poor functional (OR = 1.600, p = 0.004) and structural outcome (OR = 1.318, p = 0.043)., Conclusions: Several candidate susceptibility genes including RP1L1, RPGR, RPE65 and CCDC66 were identified to be associated with CQ/HCQ retinopathy. In addition to disease susceptibility, patients with increased genetic variants are more vulnerable to poor visual outcomes., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
35. Quality of hydroxychloroquine retinopathy screening at a Canadian teaching hospital.
- Author
-
Antaki F, El-Khoury J, Kaminska O, and Jabbour S
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Canada, Aged, Risk Factors, Mass Screening methods, Adult, Hydroxychloroquine adverse effects, Hydroxychloroquine administration & dosage, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Antirheumatic Agents adverse effects, Antirheumatic Agents administration & dosage, Hospitals, Teaching
- Abstract
Purpose: To assess the quality of hydroxychloroquine (HCQ)-induced retinopathy screening at a Canadian tertiary center, we concentrate on risk factor documentation within the electronic health record, in accordance with the 2016 AAO guidelines., Methods: We performed a retrospective quality assessment study based on chart review of patients who underwent screening for HCQ-induced retinopathy at the Centre Hospitalier de l'Université de Montréal (CHUM) from 2016 to 2019. We evaluated four key risk factors for HCQ-induced retinopathy: daily dose, duration of use, renal disease, and tamoxifen use, using a three-tier grading system (ideal, adequate, inadequate) for documentation assessment. Pareto and root cause analyses were conducted to identify potential improvement solutions., Results: Documentation quality varied in our study: daily dosage was 33% ideal, 31% appropriate, and 36% inappropriate. Duration of use documentation was 75% ideal, 2% adequate, and 24% inadequate. Renal disease documentation was only 6% ideal, with 62% adequate and 32% of charts lacking any past medical history. Among women's charts, tamoxifen use wasn't documented at all, with 65% adequately documenting medication lists. Pareto analysis indicated that improving renal disease and tamoxifen documentation could reduce 64% of non-ideal records, and enhancing daily dose documentation could decrease this by up to 90%., Conclusion: Accurate documentation of key risk factors is critical for HCQ-induced retinopathy screening, impacting both exam initiation and frequency. Our study identifies potential improvements in the screening process at the hospital, referring physician, and ophthalmologist levels. Implementing integrated pathways could enhance patient experience and screening effectiveness., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
36. A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects.
- Author
-
Feng J, Kuang SY, Wan JH, Li R, Zhu YJ, Cai BL, Guan L, and Zhang Z
- Subjects
- Humans, Male, Adult, Female, Young Adult, Healthy Volunteers, Asian People, Half-Life, Drugs, Generic pharmacokinetics, Drugs, Generic administration & dosage, Drugs, Generic adverse effects, Administration, Oral, China, East Asian People, Therapeutic Equivalency, Cross-Over Studies, Hydroxychloroquine pharmacokinetics, Hydroxychloroquine administration & dosage, Hydroxychloroquine adverse effects, Hydroxychloroquine blood, Tablets, Fasting, Food-Drug Interactions, Area Under Curve
- Abstract
Aims: Hydroxychloroquine (HCQ) has a high variability and a long half-life in the human body. The purpose of this study was to evaluate the bioequivalence of a generic HCQ tablet (test preparation) versus a brand HCQ tablet (reference preparation) under fasting and fed conditions in a crossover design., Materials and Methods: This was an open-label, two-period randomized, single-dose, crossover study in 47 healthy Chinese subjects who were sequentially and randomly allocated either to the fed group (high-fat meal; n = 23) or the fasting group (n = 24). Participants in each group were randomized to the two arms to receive either a single 200-mg dose of the test preparation or a 200-mg dose of the reference preparation. The application of the two preparations in each patient was separated by a 28-day washout period, regarded as sufficiently long to avoid significant interference from residual drug in the body. Whole blood samples were collected over 72 hours after drug administration., Results: A total of 23 subjects completed both the fed and the fasting parts of the trial. There were no significant differences in C
max , AUC0-72h , and T1/2 between the test and reference preparation (p < 0.05). Food had no significant effect on Cmax and T1/2 (p < 0.05), but AUC0-72h values were significantly reduced under fed condition compared to fasting condition (p < 0.05). The 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of Cmax and AUC0-72h were 0.84 - 1.05 and 0.89 - 0.98 in the fed study, and 0.97 - 1.07 and 0.97 - 1.05 in the fasting study, respectively. The carryover effect due to non-zero blood concentrations resulted in higher AUC0-72h values in the second period for both test and reference formulations and had no effect on the statistical results. No serious adverse events were reported., Conclusion: The investigation demonstrated that the test and reference preparations are bioequivalent and well tolerated under both fasting and fed conditions in healthy Chinese subjects.- Published
- 2024
- Full Text
- View/download PDF
37. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
- Author
-
Trefond L, Lhote R, Mathian A, de Chambrun MP, Pha M, Hie M, Miyara M, Papo M, Moyon Q, Taieb D, Saade S, Salem TB, Haroche J, Chasset F, Aubart FC, Zahr N, and Amoura Z
- Subjects
- Humans, Female, Risk Factors, Male, Adult, Case-Control Studies, Middle Aged, Antimalarials adverse effects, Antimalarials therapeutic use, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic chemically induced, Chloroquine adverse effects, Chloroquine therapeutic use, Retinal Diseases chemically induced, Antirheumatic Agents adverse effects
- Abstract
Background: Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3-8 % of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease. However, those factors cannot explain the entire risk of developing antimalarial retinopathy., Objective: This study was undertaken to identify new risk factors associated with HCQ or CQ retinopathy (QRNP) in systemic lupus erythematosus (SLE) patients., Methods: This case-control (1:2) study compared SLE patients with QRNP (cases) to those without (controls). Controls were matched for sex and known QRNP risk factors: HCQ and/or CQ treatment duration (±1 year) and age (±5 year) at SLE diagnosis., Results: Forty-eight cases were compared to 96 SLE controls. Multivariable logistic-regression analysis retained the following as independent determinants significantly associated with QRNP: concomitant selective serotonin-reuptake inhibitor (SSRI) or serotonin- and norepinephrine-reuptake inhibitor (SNRI) intake (OR [95 % confidence interval] 6.6 [1.2 to 40.9]; p < 0.01); antiphospholipid syndrome (OR=8.9 [2.2 to 41.4] p < 0.01); blood hydroxychloroquine/desethylchloroquine concentration ([HCQ]/[DCQ]) ratio <7.2 (OR 8.4 [2.7 to 30.8]; p < 0.01) or skin phototype ≥4 (OR 5.5 [1.4 to 26.5]; p = 0.02), but not daily HCQ dose, blood [HCQ] or body mass index., Conclusion: The results of this case-control study identified blood [HCQ]/[DCQ] ratio, concurrent SSRI/SNRI therapy, skin phototype ≥4 and antiphospholipid syndrome as new risk factors for QRNP., Competing Interests: Declaration of competing interest AM has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca, GSK, Novartis and Otsuka; received consulting fees, speaking fees and honoraria from AstraZeneca, GSK, Novartis and Otsuka. FC has received grant/research support from AstraZeneca; participated in advisory board related to lupus for AstraZeneca, GSK, Celgene and Principabio; received speaking fees and honoraria from AstraZeneca and GSK. ZA has received grant/research support from GSK, AstraZeneca, Roche, Novartis, Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, Otsuka; Novartis received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. The remaining authors declare no conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Systematic hydroxychloroquine retinopathy monitoring programme: cost benefit comparing to a hospital-based system.
- Author
-
Meredith SP, Palmer S, Beharrell H, Coe S, Hobbs H, and Kirby P
- Subjects
- Humans, Antirheumatic Agents adverse effects, Antirheumatic Agents economics, Female, Male, Middle Aged, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Retinal Diseases chemically induced, Cost-Benefit Analysis
- Published
- 2024
- Full Text
- View/download PDF
39. Accelerated hydroxychloroquine toxic retinopathy (response to letter).
- Author
-
Mohapatra A, Gupta P, and Ratra D
- Subjects
- Humans, Tomography, Optical Coherence, Hydroxychloroquine adverse effects, Retinal Diseases chemically induced, Antirheumatic Agents adverse effects
- Published
- 2024
- Full Text
- View/download PDF
40. Questioning accelerated hydroxychloroquine retinopathy.
- Author
-
Marmor MF
- Subjects
- Humans, Hydroxychloroquine adverse effects, Retinal Diseases chemically induced, Retinal Diseases drug therapy, Antirheumatic Agents adverse effects
- Published
- 2024
- Full Text
- View/download PDF
41. Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine.
- Author
-
Headd VA, Mathien A, Pei S, and Kuraitis D
- Subjects
- Aged, Humans, Male, Antineoplastic Agents, Immunological adverse effects, Drug Eruptions etiology, Drug Eruptions pathology, Lichenoid Eruptions chemically induced, Lichenoid Eruptions pathology, Skin Ulcer chemically induced, Skin Ulcer pathology, Hydroxychloroquine adverse effects, Nivolumab adverse effects, Penile Diseases chemically induced, Penile Diseases drug therapy, Penile Diseases pathology
- Published
- 2024
- Full Text
- View/download PDF
42. Aspects of Histopathological and Ultrastructural Retinal Changes in Chronic Exposure to Hydroxychloroquine.
- Author
-
Geamănu A, Baciu AE, Pirvulescu R, Iancu R, Anton N, Popa-Cherecheanu A, Ghita AM, and Romanitan MO
- Subjects
- Animals, Rats, Male, Antirheumatic Agents therapeutic use, Antirheumatic Agents pharmacology, Hydroxychloroquine therapeutic use, Hydroxychloroquine pharmacology, Hydroxychloroquine adverse effects, Rats, Wistar, Retina drug effects, Retina ultrastructure, Retina pathology
- Abstract
Background and Objective: Hydroxychloroquine sulfate (HCQ) is a lysosomotropic agent administered in systemic lupus erythematosus and rheumatoid arthritis that has fewer toxic effects than chloroquine. However, HCQ may still be responsible for retinal toxicity. In this study, we observed structural changes in the retinas of experimental rats after prolonged exposure to HCQ. Matherials and Methods: We investigated several aspects regarding retinal changes, at both the histopathological and ultrastructural levels. We used 96 male albino Wistar rats distributed into four equal groups (n = 24 per group): the first three groups were treated with different doses of HCQ (50, 100, and 200 mg/kg HCQ, injected intraperitoneally in a single dose daily), and the last group (the control group, n = 24) was treated with saline solution administered in the same way (0.4 mL of saline solution). The treated groups received HCQ daily for 4 months, and every month, six animals from each group were sacrificed to assess retinal changes. The eyes were examined via optical (OM) and electronic microscopy (EM). Statistical analysis was deployed, and results regarding retinal morpho-photometry were acquired. Results: We observed structural retinal changes in both high and low doses of HCQ; while high doses determined a significant thinning of the retina, lower doses caused retinal thickening. Morphological retinal changes upon exposure to HCQ are believed to be caused by accumulated HCQ in lysosomes found in retinal ganglion cells and in the inner nuclear and photoreceptor cell layers. Such changes were most evident in the group receiving HCQ intraperitoneally in doses of 100 mg/kg for a longer period (4 months). Conclusions: The present study highlights histopathological and ultrastructural retinal changes induced by chronic HCQ administration, which were strongly connected to the dosage and period of exposure.
- Published
- 2024
- Full Text
- View/download PDF
43. Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients.
- Author
-
Green M, Williams L, Boh E, and Kuraitis D
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Male, Adult, Aged, Antirheumatic Agents adverse effects, Rheumatic Diseases drug therapy, Skin Diseases diagnosis, Skin Diseases chemically induced, Skin Diseases drug therapy, Hydroxychloroquine adverse effects, Drug Monitoring methods
- Abstract
Hydroxychloroquine (HCQ) is an immunomodulator used in dermatology and rheumatology. Side effects may be observed on routine monitoring studies before they become clinically apparent. The goal of this retrospective chart review was to assess laboratory abnormalities in dermatologic and rheumatologic patients taking HCQ. Medical records of patients prescribed HCQ were retrospectively reviewed. Demographics, reported side effects, and parameters on baseline and follow-up complete blood count (CBC) and comprehensive metabolic panel (CMP) were recorded and graded. Laboratory abnormalities were considered severe if they were grade 3 or greater according to Common Terminology Criteria for Adverse Events v3.0 and persistent if they continued beyond subsequent laboratory testing. Of 646 eligible charts, 289 had monitoring studies for review. There were 35 severe (grade 3 or 4, 35/289; 12%) adverse events that developed, as noted on CBC or CMP. Of these 35 severe adverse events, 25 self-corrected on subsequent testing, and 10 (10/289, 3%) across 9 patients were persistent, including glomerular filtration rate, alanine transferase, alkaline phosphatase, glucose, hemoglobin and lymphopenia abnormalities. Of these 10 abnormalities, 7/10 (70%) were unlikely due to hydroxychloroquine use according to the calculated Naranjo score for each patient. Severe laboratory abnormalities while taking hydroxychloroquine are rare, even in a population with a high rate of comorbidities. Among the abnormalities observed, the majority of them (70%) were likely due to disease progression or a medication other than hydroxychloroquine. CBC and CMP monitoring for the reason of observing abnormalities while on HCQ should be at the discretion of the prescribing physician., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature.
- Author
-
De la Flor JC, Rodríguez-Doyágüez P, Villa D, Zamora R, and Díaz F
- Subjects
- Humans, Acute Kidney Injury chemically induced, Lipidoses chemically induced, Paraproteinemias chemically induced, Female, Aged, Amiodarone adverse effects, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Phospholipids
- Abstract
Phospholipidosis is a rare disorder which consists of an excessive intracellular accumulation of phospholipids and the appearance of zebra bodies or lamellar bodies when looking at them using electron microscopy. This disease is associated with certain genetic diseases or is secondary to drugs or toxins. Drug-induced phospholipidosis encompasses many types of pharmaceuticals, most notably chloroquine, amiodarone or ciprofloxacin. Clinically and histologically, renal involvement can be highly variable, with the diagnosis not being made until the zebra bodies are seen under an electron microscope. These findings may require genetic testing to discount Fabry disease, as its histological findings are indistinguishable. Most of the chemicals responsible are cationic amphiphilic drugs, and several mechanisms have been hypothesized for the formation of zebra bodies and their pathogenic significance. However, the relationship between drug toxicity and phospholipid accumulation, zebra bodies and organ dysfunction remains enigmatic, as do the renal consequences of drug withdrawal. We present, to our knowledge, the first case report of acute renal injury with a monoclonal gammopathy of renal significance, lesions, and sclerodermiform syndrome, with zebra bodies that were associated with the initiation of a hydroxychloroquine and amiodarone treatment, as an example of drug-induced-phospholipidosis.
- Published
- 2024
- Full Text
- View/download PDF
45. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.
- Author
-
Zamani B, Hasan-Abad AM, Rafizadeh SM, Akbari H, and Motedayyen H
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Antirheumatic Agents adverse effects, Antirheumatic Agents therapeutic use, Eye Diseases chemically induced, Skin Diseases chemically induced, Aged, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Arthritis, Rheumatoid drug therapy, Lupus Erythematosus, Systemic drug therapy, Chloroquine adverse effects
- Abstract
Immunosuppressive agents are routinely used to control autoimmunity. However, some adverse events are correlated to their clinical applications. The aim of this study was to study the clinical findings and ocular and cutaneous side effects of chloroquine (CQ) and hydroxychloroquine (HCQ), as current immunomodulators, in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This descriptive study was performed on 360 individuals referred to the Rheumatology clinic during 2003-2020. Demographic characteristics and other information were collected from patients with RA and SLE. Skin and ocular complications were evaluated in patients who were on treatment with CQ and HCQ. Study populations consisted of 199 subjects with RA and 161 cases with SLE. The frequencies of skin and ocular complications in all patients treated with CQ and HCQ were 32 (17.65%) and 94 (51.9%), respectively. The prevalence of skin complications in patients with RA and SLE was 20 (10.05%) and 22 (13.66%), respectively. The frequencies of ocular complications in patients with RA and SLE were, respectively, 58 (29.4%) and 36 (22.5%). Multiple logistic regression analysis revealed that ophthalmic complications of CQ and HCQ in all patients were dependent on the effects of the duration of drug uses, disease duration, and cumulative doses ( p < 0.05), unlike skin complications. Disease types had no effect on ocular complications. Based on these findings, treatment with CQ and HCQ participates in some skin and ocular complications in patients with RA and SLE which are largely associated with the duration of disease and treatment.
- Published
- 2024
- Full Text
- View/download PDF
46. [Hydroxychloroquine-not always a harmless drug for off label use in dermatology].
- Author
-
Seidel P, Spukti E, Steinbrink K, Metze D, and Böhm M
- Subjects
- Humans, Female, Drug Hypersensitivity Syndrome etiology, Drug Hypersensitivity Syndrome diagnosis, Drug Hypersensitivity Syndrome drug therapy, Lichen Planus drug therapy, Lichen Planus chemically induced, Lichen Planus pathology, Middle Aged, Drug Eruptions etiology, Drug Eruptions diagnosis, Drug Eruptions pathology, Drug Eruptions drug therapy, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Hydroxychloroquine administration & dosage, Off-Label Use
- Abstract
Hydroxychloroquine is used for treatment of inflammatory diseases. It is considered to have few adverse effects. We report on a woman who developed a severe skin rash after intake of hydroxychloroquine, which she received for treatment of her lichen planopilaris. Based on the clinical, laboratory and histological findings the diagnosis of a drug reaction with eosinophilia and systemic symptoms (DRESS)-like drug reaction was established. Our case illustrates that hydroxychloroquine can lead to severe adverse effects in rare cases and that patients receiving this drug must be thoroughly informed., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
47. Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes.
- Author
-
Jorge AM, Melles RB, Marmor MF, Zhou B, Zhang Y, and Choi HK
- Subjects
- Humans, Male, Female, Middle Aged, Risk Factors, Aged, Cohort Studies, Adult, California epidemiology, Antirheumatic Agents adverse effects, Hydroxychloroquine adverse effects, Retinal Diseases chemically induced, Retinal Diseases epidemiology
- Abstract
Importance: The major toxic effect of hydroxychloroquine is retinopathy. Thus, current guidelines recommend limiting the dose and screening annually for retinopathy among all long-term users, but individual patient factors may be associated with retinopathy risk., Objective: To identify risk factors beyond hydroxychloroquine dose and duration of use for hydroxychloroquine retinopathy., Design, Setting, and Participants: This cohort study of 4677 patients in the Kaiser Permanente Northern California integrated health network who initiated hydroxychloroquine, continued treatment, and underwent retinopathy screening after 5 years of use was conducted from July 1, 1997, to December 31, 2020, with up to 15 years of follow-up. Statistical analysis was performed in August 2023., Exposure: Candidate risk factors included age at hydroxychloroquine initiation, sex, race and ethnicity, indications, chronic kidney disease (CKD), liver disease, diabetes, tamoxifen use, and medications that interact with hydroxychloroquine metabolism. Hydroxychloroquine dose was assessed from pharmacy dispensing records., Main Outcome and Measures: Incident hydroxychloroquine retinopathy was adjudicated from masked review of guideline-recommended screening studies and classified as parafoveal or pericentral pattern. Multivariable Cox proportional hazards regression was used to assess potential risk factors for hydroxychloroquine retinopathy within 15 years of initiation., Results: Of 4677 long-term hydroxychloroquine users (mean [SD] age at initiation, 52.4 [14.1] years; 3877 women [82.9%]), 125 patients developed hydroxychloroquine retinopathy within 15 years (102 parafoveal, 23 pericentral). Older age at time of hydroxychloroquine initiation was associated with retinopathy risk, with adjusted hazard ratios (HRs) of 2.48 (95% CI, 1.28-4.78) for those aged 45 to 54 years, 3.82 (95% CI, 2.05-7.14) for those aged 55 to 64 years, and 5.68 (95% CI, 2.99-10.79) for those aged 65 years or older compared with those younger than 45 years. The risk of retinopathy was higher among females than males (HR, 3.83 [95% CI, 1.86-7.89]), among patients with CKD stage 3 or greater (HR, 1.95 [95% CI, 1.25-3.04]), and among individuals with tamoxifen use (HR, 3.43 [95% CI, 1.08-10.89]). The likelihood of pericentral retinopathy was higher among Asian patients (HR, 15.02 [95% CI, 4.82-46.87]) and Black patients (HR, 5.51 [95% CI, 1.22-24.97]) compared with non-Hispanic White patients., Conclusions and Relevance: This study suggests that increasing age, female sex, CKD stage 3 or greater, and tamoxifen use were associated with a higher risk of hydroxychloroquine retinopathy, whereas being younger than 45 years at hydroxychloroquine initiation and male sex were associated with a lower risk. Race and ethnicity were also associated with the pattern of retinopathy. These factors should be incorporated into hydroxychloroquine dosing decisions.
- Published
- 2024
- Full Text
- View/download PDF
48. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
- Author
-
He WJ, Wang J, Liu N, Li GY, Zhu XW, Yao L, and Liu LL
- Subjects
- Humans, Female, Male, Retrospective Studies, Adult, Middle Aged, Treatment Outcome, Hematuria chemically induced, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Drug Therapy, Combination, Renin-Angiotensin System drug effects, Leflunomide therapeutic use, Leflunomide adverse effects, Glomerulonephritis, IGA drug therapy, Glomerulonephritis, IGA physiopathology, Hydroxychloroquine therapeutic use, Hydroxychloroquine adverse effects, Glomerular Filtration Rate drug effects, Proteinuria, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensin-Converting Enzyme Inhibitors adverse effects
- Abstract
Purpose: To date, our understanding of IgA nephropathy (IgAN) pathophysiology has remained incomplete; therefore, treatment remains largely empiric, and the efficacy and safety of immunosuppressants remain controversial. We aimed to assess the efficacy and safety of hydroxychloroquine and leflunomide therapy in a retrospective cohort of patients with IgAN., Methods: We screened the IgAN registration database in our department, and a total of 159 kidney patients with biopsy-confirmed IgAN were enrolled, with 57 patients receiving hydroxychloroquine plus a renin-angiotensin system inhibitor (hydroxychloroquine group), 52 patients receiving leflunomide plus a renin-angiotensin system inhibitor (leflunomide group), and 50 patients receiving only a renin-angiotensin system inhibitor (renin-angiotensin system inhibitor-only group). Changes in proteinuria, hematuria, and the estimated glomerular filtration rate (eGFR), as well as adverse events, were analyzed during the follow-up period., Results: At the end of 6-month follow-up, proteinuria significantly decreased by 70.36 (57.54, 79.33)%, 57.29 (46.79, 67.29)% and 41.20 (25.76, 48.94)% in the hydroxychloroquine, leflunomide and renin-angiotensin system inhibitor-only groups, respectively, compared to baseline (all P values < 0.001). Hematuria significantly decreased by 71.07 (56.48, 82.47)% in the leflunomide group (P < 0.001). The eGFR improved by 3.72 ± 2.97%, 3.16 ± 2.00% and 1.91 ± 2.41%, respectively, in the hydroxychloroquine, leflunomide and renin-angiotensin system inhibitor-only groups, but without statistical significance. No serious adverse events occurred during the follow-up period., Conclusion: Both hydroxychloroquine combined with a renin-angiotensin system inhibitor and leflunomide combined with a renin-angiotensin system inhibitor were more effective than a renin-angiotensin system inhibitor alone in improving proteinuria in IgAN patients. Hydroxychloroquine was more effective in reducing proteinuria, and leflunomide showed superiority in reducing hematuria. Our results need to be verified in large-scale randomized controlled trials., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
49. Hydroxychloroquine-Induced Nonthrombocytopenic Purpura: A Case Series.
- Author
-
Aoki KC, Bartos G, and Skopit S
- Subjects
- Humans, Purpura, Thrombotic Thrombocytopenic chemically induced, Purpura, Thrombotic Thrombocytopenic diagnosis, Antirheumatic Agents adverse effects, Hydroxychloroquine adverse effects, Hydroxychloroquine administration & dosage
- Abstract
Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic medication for the treatment of various autoimmune conditions. A rare side effect of HCQ is thrombotic thrombocytopenic purpura (TTP). We present two cases of patients who developed purpura that did not meet TTP criteria following treatment with HCQ. While the etiology of HCQ-associated TTP is poorly understood, we propose a spectrum of manifestations related to HCQ, ranging from benign purpura to TTP. As multiple factors contribute to the disease, we believe that HCQ may act as a "second hit" in patients with genetic susceptibility, which also influences the variability in the severity of disease manifestations. J Drugs Dermatol. 2024;23(5):e124. doi:10.36849/JDD.7781e.
- Published
- 2024
- Full Text
- View/download PDF
50. RAPID ONSET HYDROXYCHLOROQUINE TOXICITY.
- Author
-
Jeltsch BM, Sarraf D, Madjdpour D, Hanson JVM, Pfiffner FK, Koller S, Berger W, Barthelmes D, and Al-Sheikh M
- Subjects
- Humans, Female, Middle Aged, Arthritis, Rheumatoid drug therapy, Electroretinography, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Fluorescein Angiography, Visual Acuity, Visual Fields drug effects, Retina drug effects, Retina pathology, Retinal Degeneration chemically induced, Retinal Degeneration diagnosis, Hydroxychloroquine adverse effects, Antirheumatic Agents adverse effects, Tomography, Optical Coherence
- Abstract
Purpose: Hydroxychloroquine (HCQ) can cause irreversible damage to the retina, especially when taken over longer periods. The American Academy of Ophthalmology recommends a regimen for dosing, screening, and monitoring of patients treated with HCQ. We present an unusual case of a rapid development of severe HCQ-associated retinopathy already after 2 years after commencing HCQ treatment., Methods: Observational case report. Clinical examination, optical coherence tomography, fundus autofluorescence imaging, perimetry, and full-field and multifocal electroretinography were performed. Ancillary tests included neoplastic and paraneoplastic work-up, vitamin levels, and whole-exome sequencing, to rule out other potential causes of a panretinal degeneration., Results: We report on a 58-year-old woman with rheumatoid arthritis, treated initially with 200 mg HCQ daily for 1 year (daily dose 3.6 mg/kg), then 400 mg daily for 1 year (daily dose 7.2 mg/kg), and a cumulative dose of 216 g. Her medical history was otherwise unremarkable. No family history for inherited retinal conditions. She was referred due to a rapid and sudden progressive and severe concentric visual field constriction, 2 years after commencing HCQ treatment., Conclusion: This case of a rapid-onset, severe panretinal degeneration shortly after start of HCQ treatment suggests underlying mechanisms and risk factors for HCQ toxicity in addition to those previously reported and a potential need for supplementary screening tests to prevent HCQ toxicity. American Academy of Ophthalmology dosing guidelines of 5 mg/kg should be strictly adhered to in patients receiving HCQ therapy., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.